Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230012/S012

UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System

Alcon Research, LLC · Decision date Sep 30, 2026

MEDTECHLEDGER EXPLANATIONP230012/S012

What did the FDA decide?

FDA recorded a 30-Day Notice decision (OK30) dated 2026-09-30 for P230012/S012, a supplement to the UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System, submitted by Alcon Research, LLC. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier. The recorded scope covers three manufacturing changes: an alternate supplier for UNIFEYE screen and pad printing operations, an alternate third-party supplier of ink and additive for printed components, and an alternate third-party supplier for machining and passivating the Valve Seat component.

This action concerns the manufacturing supply chain for the delivery system rather than a new approval of the gas or the complete system. The device category is gases used within the eye to place pressure on a detached retina, with ophthalmic specialty and product code LPO. No supporting documents were included in the source record, so the review basis, any testing performed and whether labeling changed remain unknown.

The OK30 code is reported as recorded; its precise administrative meaning is not defined in the source data and is not interpreted here.

FDA approval order statement

Approval of implementing the following manufacturing changes: 1) Alternate supplier for the UNIFEYE screen and pad printing operations; 2) Alternate ink and additive third-party supplier for the UNIFEYE printed components; 3) Alternate third-party supplier to perform the machining and passivating processes for the Valve Seat component.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Sep 30, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230012/S012
Regulatory pathway
PMA supplement
Product code
LPO
Decision code
OK30
Decision date
Sep 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Gases used within eye to place pressure on detached retina.

Product code
LPO
FDA device class
3

For the original device and its historical approval scope, see PMA P230012. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230012 · Original PMA

    UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System, UNIPURE SF6 Ophthalmic Gas in the UNIPEXY Gas Delivery Sy

  2. P230012/S012 received

    Application receipt date recorded by FDA.

  3. P230012/S012 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P230012. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230012

Explore the linked device profile

Other records with product code LPO

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Alcon Research, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
20511 Lake Forest Dr., Lake Forest, CA, 92630

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records